These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 1818384)

  • 41. Immunogenicity of measles and rubella vaccines in Oman: a prospective clinical trial.
    Kohler KA; Suleiman AJ; Robertson SE; Malankar P; Al-Khusaiby S; Helfand RF; Brown D; Bellini WJ; Sutter RW
    J Infect Dis; 2003 May; 187 Suppl 1():S177-85. PubMed ID: 12721911
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Two-dose measles vaccination schedules.
    Rosenthal SR; Clements CJ
    Bull World Health Organ; 1993; 71(3-4):421-8. PubMed ID: 8324862
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial.
    Dilraj A; Cutts FT; de Castro JF; Wheeler JG; Brown D; Roth C; Coovadia HM; Bennett JV
    Lancet; 2000 Mar; 355(9206):798-803. PubMed ID: 10711928
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Divergent mortality for male and female recipients of low-titer and high-titer measles vaccines in rural Senegal.
    Aaby P; Samb B; Simondon F; Knudsen K; Seck AM; Bennett J; Whittle H
    Am J Epidemiol; 1993 Nov; 138(9):746-55. PubMed ID: 8237989
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expanded programme on immunization (EPI). Safety of high titre measles vaccines.
    Wkly Epidemiol Rec; 1992 Nov; 67(48):357-61. PubMed ID: 1449986
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial.
    Aaby P; Martins CL; Garly ML; Balé C; Andersen A; Rodrigues A; Ravn H; Lisse IM; Benn CS; Whittle HC
    BMJ; 2010 Nov; 341():c6495. PubMed ID: 21118875
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Trial of high-dose Edmonston-Zagreb measles vaccine in Guinea-Bissau: protective efficacy.
    Aaby P; Jensen TG; Hansen HL; Kristiansen H; Thårup J; Poulsen A; Sodemann M; Jakobsen M; Knudsen K; Clotilde da Silva M
    Lancet; 1988 Oct; 2(8615):809-11. PubMed ID: 2902263
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reduced seroconversion to measles in infants given vitamin A with measles vaccination.
    Semba RD; Munasir Z; Beeler J; Akib A; Muhilal ; Audet S; Sommer A
    Lancet; 1995 May; 345(8961):1330-2. PubMed ID: 7752754
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and safety of standard-titer AIK-C measles vaccine in nine-month-old infants.
    Tsai HY; Huang LM; Shih YT; Chen JM; Jiang TM; Tsai CH; Lee CY
    Viral Immunol; 1999; 12(4):343-8. PubMed ID: 10630793
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Measles virus antibody responses in children randomly assigned to receive standard-titer edmonston-zagreb measles vaccine at 4.5 and 9 months of age, 9 months of age, or 9 and 18 months of age.
    Martins C; Garly ML; Bale C; Rodrigues A; Njie-Jobe J; Benn CS; Whittle H; Aaby P
    J Infect Dis; 2014 Sep; 210(5):693-700. PubMed ID: 24688075
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants.
    Cutts FT; Grabowsky M; Markowitz LE
    Biologicals; 1995 Mar; 23(1):95-106. PubMed ID: 7619443
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of dose and strain of vaccine on success of measles vaccination of infants aged 4-5 months.
    Whittle HC; Mann G; Eccles M; O'Neill K; Jupp L; Hanlon P; Hanlon L; Marsh V
    Lancet; 1988 Apr; 1(8592):963-6. PubMed ID: 2896828
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Head-to-head immunogenicity comparison of Edmonston-Zagreb vs. AIK-C measles vaccine strains in infants aged 8-12 months: A randomized clinical trial.
    Izadi S; Zahraei SM; Salehi M; Mohammadi M; Tabatabaei SM; Mokhtari-Azad T
    Vaccine; 2018 Jan; 36(5):631-636. PubMed ID: 29289382
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lessons from measles vaccination in developing countries.
    Hall AJ; Cutts FT
    BMJ; 1993 Nov; 307(6915):1294-5. PubMed ID: 8257878
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibody persistence in Gambian children after high-dose Edmonston-Zagreb measles vaccine.
    Whittle HC; Campbell H; Rahman S; Armstrong JR
    Lancet; 1990 Oct; 336(8722):1046-8. PubMed ID: 1977029
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The transmission of maternal measles antibodies to newborn infants in the Ivory Coast].
    Rey JL; Lhuillier M; Dem M; Soro B; Saki Z; Davis CE
    Med Trop (Mars); 1991; 51(2):215-8. PubMed ID: 1654494
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Model-based comparisons of measles immunization strategies using high dose Edmonston-Zagreb type vaccines.
    McLean AR; Nokes DJ; Anderson RM
    Int J Epidemiol; 1991 Dec; 20(4):1107-17. PubMed ID: 1800411
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protecting infants against measles in England and Wales: a review.
    Manikkavasagan G; Ramsay M
    Arch Dis Child; 2009 Sep; 94(9):681-5. PubMed ID: 19457878
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial.
    Martins CL; Garly ML; Balé C; Rodrigues A; Ravn H; Whittle HC; Lisse IM; Aaby P
    BMJ; 2008 Jul; 337():a661. PubMed ID: 18653640
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Measles immunisation before the age of nine months? Position statement by the expanded programme on immunisation of the World Health Organisation.
    Lancet; 1988 Dec; 2(8624):1356-7. PubMed ID: 2904064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.